{"prompt": "['056-F275, Clinical Investigation Plan Template, Version 2.0', 'Page 9 of 115', '15.2.', 'Risk Minimization', '51', '15.3.', 'Potential Benefits', '52', '15.4.', 'Risk-Benefit Rationale', '52', '16.', 'Adverse Event and Device Deficiencies Assessment', '52', '16.1.', 'Adverse Event and Device Deficiency Definitions', '53', '16.2.', 'Adverse Events', '55', '16.3.', 'Device Deficiencies', '56', '16.4.', 'Processing Updates and Resolution', '56', '16.5.', 'Reporting of Adverse Events and Device Deficiencies', '56', '16.6.', 'Subject Death', '63', '16.6.1.', 'Death Classification and Reporting', '63', '16.7.', 'Product Complaint Reporting', '63', '17.', 'Data Review Committees', '64', '18.', 'Statistical Design and Methods', '65', '18.1.', 'General Considerations', '65', '18.2.', 'Analysis Timing', '65', '18.2.1.', 'PMA-S Submission', '65', '18.2.2.', 'PMDA Submission', '65', '18.3.', 'Primary Objectives', '65', '18.3.1.', 'Primary Efficacy Objective', '65', '18.3.2.', 'Primary Safety Objective', '70', '18.4.', 'Secondary Objective', '74', '18.4.1.', 'Secondary Objective: Quality of Life - Atrial Fibrillation Effect on QualiTy-of-life', '(AFEQT) and SF-12 Questionnaires', '74', '18.5.', 'Ancillary Objectives', '76', '18.5.1.', '76', '18.5.2.', '77', '18.5.3.', '78', '18.5.4.', '78', '18.5.5.', '79', '18.5.6.', '79', '19. Ethics', '80', '19.1.', 'Statement(s) of Compliance', '80', '20.', 'Study Administration', '82', '20.1.', 'Monitoring', '82', '20.2.', 'Data Management', '82', '20.3.', 'Confidentiality', '83', '20.4.', 'CIP Amendments', '83', '20.5.', 'Record Retention', '84', '20.5.1.', 'Investigator Records', '84', '20.5.2.', 'Investigator Reports', '85', '20.5.3.', 'Sponsor Records', '87', '20.5.4.', 'Sponsor Reports', '88', 'Version 4, 10NOVO016', 'Confidential']['056-F275, Clinical Investigation Plan Template, Version 2.0', 'Page 10 of 115', '20.6.', 'Publication and Use of Information', '92', '20.7.', 'Suspension or Early Termination', '94', '20.7.1.', 'Early Termination or Suspension', '94', '20.7.2.', 'Study-wide Termination or Suspension', '94', '20.7.3.', 'Investigator/Center Termination or Suspension', '94', '20.7.4.', 'Procedures for Termination or Suspension', '95', '20.7.4.1.', 'Medtronic-Initiated and Regulatory Authority-Initiated', '95', '20.7.4.2.', 'Investigator-Initiated', '95', '20.7.4.3.', 'IRB/MEC Initiated', '96', '21. Warranty/Insuranc Information', '96', '21.1. Warranty', '96', '21.2.', 'Insurance (US)', '96', '21.3.', 'Insurance (Canada)', '96', '21.4.', 'Insurance (Europe)', '96', '21.5.', 'Insurance (Japan)', '97', '22.', 'References', '97', '23.', 'Appendices', '99', 'Version 4, 10NOVO016', 'Confidential']\n\n###\n\n", "completion": "END"}